Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BMRN | NASDAQ | USD | Real-time | |
1BMRN | Milan | EUR | Real-time | |
BMRN | TradeGate | EUR | Delayed | |
B1MR34 | B3 | BRL | Delayed | |
BMRN | Vienna | EUR | Real-time |
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Name | Age | Since | Title |
---|---|---|---|
Robert J. Hombach | 57 | 2017 | Independent Director |
Elizabeth McKee Anderson | 66 | 2019 | Independent Director |
Elaine J. Heron | 76 | 2002 | Independent Director |
Richard A. Meier | 63 | 2006 | Independent Chairman of the Board |
Alexander Hardy | 55 | 2023 | President, CEO & Director |
David E. I. Pyott | 71 | 2016 | Independent Director |
Willard H. Dere | 70 | 2016 | Independent Director |
Maykin Ho | 71 | 2021 | Independent Director |
Athena Maria Countouriotis | 52 | 2023 | Independent Director |
Mark Joseph Enyedy | 60 | 2023 | Independent Director |
Barbara W. Bodem | 56 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review